Washington, D.C. – The Food and Drug Administration (FDA) is currently investigating the potential link between Diamond Shruumz products and two reported deaths, following the recall of their microdosing products in June. The agency revealed this update to the public amidst concerns over illnesses suspected to be associated with Diamond Shruumz items.
According to the FDA, as of July 22, 2024, there have been a total of 74 reported illnesses in 28 states, with 62 individuals seeking medical care and 38 requiring hospitalization. Of the reported cases, there are two deaths currently under investigation for their potential connection to the products.
Diamond Shruumz, known for marketing “microdose” edibles, has recalled all its microdosing chocolate bars, infused cones, and gummies. Despite their claim that their products do not contain psychedelic substances, recent findings suggest otherwise. It was discovered that some of their gummies contained psilocin, a Schedule 1 substance illegal in certain states.
Prophet Premium Blends, the parent company of Diamond Shruumz, initiated the recall of all products in collaboration with the FDA. The recall notice cited the presence of muscimol, a psychoactive compound found in Amanita muscaria, which may be responsible for symptoms observed in individuals who fell ill after consuming the products.
Consumers who reported adverse effects after ingesting Diamond Shruumz products experienced a range of symptoms, including seizures, abnormal heart rates, and vomiting. The FDA issued an initial advisory in June to avoid their microdosing chocolate bars, subsequently expanding it to include other products as new information emerged.
In response to the situation, Diamond Shruumz has urged consumers to refrain from using their products while investigations continue. The CDC also cautioned against the consumption of psychedelic or nootropic mushroom gummies due to potential mislabeling and the presence of harmful substances.
Despite attempts to contact Diamond Shruumz for comment, representatives have not responded. The FDA has emphasized the need for caution and vigilance in consuming similar products to prevent unexpected and harmful effects on consumers.